# DeLLphi-309 (NCT06745323)

> A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06745323
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Small Cell Lung Cancer (SCLC)
- Interventions: Tarlatamab
- Enrollment: 252
- Primary outcome: Proportion of participants with confirmed objective response to Tarlatamab
- Primary outcome: Proportion of participants with complete response to Tarlatamab
- Primary outcome: Proportion of participants with partial response to Tarlatamab

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dellphi-309-nct06745323